MA35086B1 - Compose de triazolopyridine - Google Patents
Compose de triazolopyridineInfo
- Publication number
- MA35086B1 MA35086B1 MA36027A MA36027A MA35086B1 MA 35086 B1 MA35086 B1 MA 35086B1 MA 36027 A MA36027 A MA 36027A MA 36027 A MA36027 A MA 36027A MA 35086 B1 MA35086 B1 MA 35086B1
- Authority
- MA
- Morocco
- Prior art keywords
- triazolopyridine
- compound
- formula
- relates
- triazolopyridine compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 title 1
- 150000008523 triazolopyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention concerne des composés de triazolopyridine de formule (i), dans laquelle r
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10194014 | 2010-12-07 | ||
| PCT/EP2011/071685 WO2012076430A1 (fr) | 2010-12-07 | 2011-12-05 | Composés de triazolopyridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35086B1 true MA35086B1 (fr) | 2014-05-02 |
Family
ID=45099086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36027A MA35086B1 (fr) | 2010-12-07 | 2013-06-20 | Compose de triazolopyridine |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8349824B2 (fr) |
| EP (1) | EP2649070B1 (fr) |
| JP (1) | JP5932828B2 (fr) |
| KR (1) | KR20130128426A (fr) |
| CN (1) | CN103237803B (fr) |
| AR (1) | AR084152A1 (fr) |
| AU (1) | AU2011340685A1 (fr) |
| BR (1) | BR112013013912A2 (fr) |
| CA (1) | CA2816829C (fr) |
| CL (1) | CL2013001591A1 (fr) |
| CO (1) | CO6741154A2 (fr) |
| CR (1) | CR20130239A (fr) |
| CY (1) | CY1115863T1 (fr) |
| DK (1) | DK2649070T3 (fr) |
| EA (1) | EA022607B1 (fr) |
| EC (1) | ECSP13012667A (fr) |
| ES (1) | ES2520647T3 (fr) |
| HR (1) | HRP20141200T1 (fr) |
| IL (1) | IL225969A0 (fr) |
| MA (1) | MA35086B1 (fr) |
| MX (1) | MX2013006054A (fr) |
| PE (1) | PE20140226A1 (fr) |
| PH (1) | PH12013500942A1 (fr) |
| PL (1) | PL2649070T3 (fr) |
| PT (1) | PT2649070E (fr) |
| RS (1) | RS53677B1 (fr) |
| SG (1) | SG190305A1 (fr) |
| SI (1) | SI2649070T1 (fr) |
| UA (1) | UA109037C2 (fr) |
| WO (1) | WO2012076430A1 (fr) |
| ZA (1) | ZA201303811B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013043518A1 (fr) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Composés imidazopyridyliques utilisables en tant qu'inhibiteurs de l'aldostérone synthase |
| EP2757883B1 (fr) * | 2011-09-22 | 2021-01-13 | Merck Sharp & Dohme Corp. | Composés triazolopyridyle à utiliser en tant qu'inhibiteurs de l'aldostérone synthase |
| ES2558618T3 (es) * | 2012-02-09 | 2016-02-05 | F. Hoffmann-La Roche Ag | Procedimiento para la preparación de derivados 2-fenil-[1,2,4]triazolo[1,5-A]piridina |
| EP2951176A1 (fr) * | 2013-01-31 | 2015-12-09 | F. Hoffmann-La Roche AG | Composés radiomarqués |
| TR201904614T4 (en) | 2013-02-27 | 2019-05-21 | Mochida Pharm Co Ltd | Novel pyrazole derivative. |
| CN105164126B (zh) * | 2013-04-30 | 2017-05-31 | 豪夫迈·罗氏有限公司 | 吡唑酰胺的Pd‑催化偶联 |
| JP6327483B2 (ja) * | 2013-05-31 | 2018-05-23 | 日産化学工業株式会社 | 複素環アミド化合物 |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| CA2956268A1 (fr) * | 2014-07-30 | 2016-02-04 | Mochida Pharmaceutical Co., Ltd. | Procede de fabrication d'un derive de pyrazole |
| KR20170032328A (ko) | 2014-07-30 | 2017-03-22 | 모찌다 세이야쿠 가부시끼가이샤 | 피라졸 유도체의 제조 방법 |
| JP6745594B2 (ja) * | 2015-11-26 | 2020-08-26 | 持田製薬株式会社 | ピラゾール誘導体の塩の結晶 |
| WO2020021024A1 (fr) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Composés bicycliques substitués en tant que modulateurs du récepteur d'hydrocarbures aryle (ahr) |
| IL327564A (en) * | 2020-06-05 | 2026-05-01 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome |
| US12544364B2 (en) | 2020-06-05 | 2026-02-10 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
| CN117157077A (zh) * | 2021-01-28 | 2023-12-01 | 诺埃玛制药公司 | 儿童期发病的流畅性障碍的治疗方法 |
| JP2024505515A (ja) * | 2021-01-28 | 2024-02-06 | ノエマ ファーマ アクツィエンゲゼルシャフト | 小児期発症流暢症の治療のための方法 |
| WO2026068583A1 (fr) | 2024-09-25 | 2026-04-02 | Noema Pharma Ag | Utilisation de l'inhibiteur de phosphodiestérase 10 gemlapodect pour la perte de poids |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1651251A4 (fr) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
-
2011
- 2011-12-01 US US13/308,588 patent/US8349824B2/en active Active
- 2011-12-05 DK DK11791543.9T patent/DK2649070T3/da active
- 2011-12-05 WO PCT/EP2011/071685 patent/WO2012076430A1/fr not_active Ceased
- 2011-12-05 AU AU2011340685A patent/AU2011340685A1/en not_active Abandoned
- 2011-12-05 UA UAA201308329A patent/UA109037C2/uk unknown
- 2011-12-05 SG SG2013037676A patent/SG190305A1/en unknown
- 2011-12-05 EA EA201390799A patent/EA022607B1/ru not_active IP Right Cessation
- 2011-12-05 PH PH1/2013/500942A patent/PH12013500942A1/en unknown
- 2011-12-05 JP JP2013542480A patent/JP5932828B2/ja active Active
- 2011-12-05 HR HRP20141200AT patent/HRP20141200T1/hr unknown
- 2011-12-05 KR KR1020137016458A patent/KR20130128426A/ko not_active Ceased
- 2011-12-05 RS RS20140574A patent/RS53677B1/sr unknown
- 2011-12-05 MX MX2013006054A patent/MX2013006054A/es active IP Right Grant
- 2011-12-05 CN CN201180057674.XA patent/CN103237803B/zh active Active
- 2011-12-05 BR BR112013013912A patent/BR112013013912A2/pt not_active Application Discontinuation
- 2011-12-05 PE PE2013001371A patent/PE20140226A1/es not_active Application Discontinuation
- 2011-12-05 AR ARP110104533A patent/AR084152A1/es unknown
- 2011-12-05 SI SI201130309T patent/SI2649070T1/sl unknown
- 2011-12-05 PT PT117915439T patent/PT2649070E/pt unknown
- 2011-12-05 CA CA2816829A patent/CA2816829C/fr active Active
- 2011-12-05 ES ES11791543.9T patent/ES2520647T3/es active Active
- 2011-12-05 PL PL11791543T patent/PL2649070T3/pl unknown
- 2011-12-05 EP EP11791543.9A patent/EP2649070B1/fr active Active
-
2013
- 2013-04-25 CO CO13105814A patent/CO6741154A2/es active IP Right Grant
- 2013-04-25 IL IL225969A patent/IL225969A0/en unknown
- 2013-05-22 CR CR20130239A patent/CR20130239A/es unknown
- 2013-05-24 ZA ZA2013/03811A patent/ZA201303811B/en unknown
- 2013-06-04 CL CL2013001591A patent/CL2013001591A1/es unknown
- 2013-06-06 EC ECSP13012667 patent/ECSP13012667A/es unknown
- 2013-06-20 MA MA36027A patent/MA35086B1/fr unknown
-
2014
- 2014-11-14 CY CY20141100951T patent/CY1115863T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35049B1 (fr) | Triazolopyridines | |
| MA35926B1 (fr) | Pyrrolidine-2-carboxamides substitués | |
| MA35089B1 (fr) | Inhibiteurs de la production de leucotrienes de type benzodioxane | |
| MA35664B1 (fr) | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one | |
| MA37940A2 (fr) | Nouveaux dérivés bicycliques | |
| MA35357B1 (fr) | Composes de type anilines | |
| MA37519A1 (fr) | Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 | |
| MA38645B1 (fr) | Nouveaux inhibiteurs de cyp17/antiandrogènes | |
| MA35245B1 (fr) | Pyridin-2-amides utiles comme agonistes de cb2 | |
| MA35452B1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante | |
| MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
| CR20120295A (es) | Triazolopiridinas | |
| MA34644B1 (fr) | Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2 | |
| CO6852084A2 (es) | Nuevos compuestos sustituidos con halógeno | |
| MX350892B (es) | Síntesis de compuesto antiviral. | |
| AU2011232516A8 (en) | Chemical compounds | |
| CR20130129A (es) | Anàlogos de buprenorfina | |
| MA34389B1 (fr) | Nouvelles aminopyrazoloquinazolines | |
| AU2014270524A8 (en) | 2-phenylimidazo [1,2-a]pyrimidines as imaging agents | |
| CR20120637A (es) | Triazolopiridinas sustituidas | |
| CR20130470A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA | |
| MA37686A1 (fr) | Composés phénoxyéthyl pipéridine | |
| UA107455C2 (uk) | Похідні індолу як протиракові агенти | |
| MX372721B (es) | Ánalogos halogenados de agentes antifi-broticos. | |
| PA8792101A1 (es) | Nuevo procedimiento de sintesis del ( 7-metoxi-1- naftil) aceto |